Inventiva to present at EASL Liver Congress 2024

May 22, 2024 - Inventiva, a biopharmaceutical company at the clinical development stage, focused on oral small molecule therapies for treating metabolic dysfunction-associated steatohepatitis (MASH), also known as non-alcoholic steatohepatitis (NASH), announced the selection of two scientific abstracts for poster presentations at the upcoming International Liver Congress 2024. This event, hosted by the European Association for the Study of the Liver (EASL), will take place from June 5-8, 2024, in Milan, Italy.

First Abstract: MACK-3 and Lanifibranor Therapy

The first abstract delves into the efficacy of the biomarker algorithm MACK-3 in diagnosing active MASH/NASH and tracking its response to lanifibranor therapy. MACK-3, comprising HOMA-IR, AST, and CK-18, effectively parallels histological improvements in liver conditions. During a 24-week treatment period, patients treated with lanifibranor who were classified as responders showed a marked reduction in MACK-3 values. These responders exhibited better outcomes in endpoints such as "MASH/NASH resolution and fibrosis improvement," "Fibrosis improvement without worsening of MASH/NASH," and "MASH/NASH resolution without fibrosis worsening," compared to non-responders. Additionally, improvements were noted in NAS, SAF scores, and individual liver lesions like steatosis, lobular inflammation, and ballooning. MACK-3 improvements were also linked with increased adiponectin levels and decreased Pro-C3, a marker for fibrogenesis, suggesting that MACK-3 could be a useful indicator for assessing treatment response to lanifibranor.

Second Abstract: Lanifibranor's Impact on MASLD-Related Vascular Alterations

The second abstract provides insights into the effects of lanifibranor on liver histology and vascular alterations in early metabolic dysfunction-associated steatotic liver disease (MASLD). Increased intrahepatic vascular resistance due to endothelial dysfunction is a potential driver of MASLD progression. The study revealed that lanifibranor significantly improved liver steatosis, normalized arterial blood pressure, decreased portal pressure in vivo, and normalized the transhepatic pressure gradient ex vivo. Furthermore, lanifibranor reduced reactivity to the vasoconstrictor methoxamine and normalized hyporeactivity to the vasodilator acetylcholine. This research underscores the role of intrahepatic vascular alterations in developing MASLD-related portal hypertension and progressing to MASH. It highlights lanifibranor's potential to address various components of MASH disease.

Presentation Details

- Abstract #1: "Improvements in MACK-3, a diagnostic test for active metabolic dysfunction-associated steatohepatitis, parallel response to lanifibranor therapy" (Poster identifier: SAT-206). Presentation on Saturday, June 8, 2024, from 8:30 to 17:00 (CEST).
- Abstract #2: "Altered liver vascular biology occurring in early stages of metabolic dysfunction-associated steatotic liver disease is significantly improved by the pan-peroxisome proliferator-activated receptor agonist lanifibranor, associating with improved liver histology" (Poster identifier: THU-258-YI). Presentation on Thursday, June 6, 2024, from 8:30 to 17:00 (CEST).

Inventiva invites attendees to visit their booth, #N4, in the exhibition hall 3 from June 5th to June 8th for further information.

About Inventiva

Inventiva is dedicated to creating oral small molecule therapies for MASH/NASH and other diseases with high unmet medical needs. Their lead candidate, lanifibranor, is in a pivotal Phase III clinical trial (NATiV3) for treating MASH/NASH. Their pipeline includes odiparcil for adult MPS VI patients, although its clinical development has been suspended to focus on lanifibranor. Inventiva boasts a team of around 90 experts and an extensive compound library, advancing innovation in nuclear receptors, transcription factors, and epigenetic modulation.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!